Attenuation of morphine-induced delirium in palliative care by substitution with infusion of oxycodone

Journal of Pain and Symptom Management

Volumn 12, Issue 3, 1996, Pages 182-189

  Maddocks, Ian ^a   Somogyi, Andrew ^b   Abbott, Fay ^c   Hayball, Peter ^c   Parker, Deborah ^a  

^a Daw House Hospice   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c REPATRIATION GENERAL HOSPITAL   (Australia)

Author keywords

delirium; Oxycodone; pain; palliative treatment

Indexed keywords

AMITRIPTYLINE; CODEINE; DOMPERIDONE; FENTANYL; HALOPERIDOL; METOCLOPRAMIDE; MORPHINE; ONDANSETRON; OXAZEPAM; OXYCODONE; PARACETAMOL; PERICIAZINE; PROCHLORPERAZINE; TEMAZEPAM;

ADULT; AGED; ANALGESIA; ARTICLE; CANCER PAIN; CANCER PALLIATIVE THERAPY; CLINICAL ARTICLE; DELIRIUM; DRUG EFFICACY; FEMALE; HUMAN; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PAIN ASSESSMENT; PHENOTYPE; SUBCUTANEOUS DRUG ADMINISTRATION; VOMITING;

EID: 0030246852     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/0885-3924(96)00050-4     Document Type: Article

References (26)

1. 1. Kalso E, Vainio A, Manri J, Rosenberg P, Seppala T. Morphine and oxycodone in the management of cancer pain: plasma levels determined by chemical and radioreceptor assays. Pharmacol Toxicol 1990;67:322-328.
2. 2. Kalso E, Vainio A. Morphine and oxycodone hydrochloride in the management of cancer pain. Clin Pharmacol Ther 1990;47:639-646.
3. 3. Smith MT, Leow KP, Crammond TR. Clinical pharmacology of oxycodone in cancer patients (Abstract from the Australian Pharmaceutical Sciences Association Scientific Meeting, Brisbane, Australia, 8-9 Dec 1993). Aust J Hosp Pharmacy 1994; 24:206.
4. 4. Leow KP, Smith MT, Williams B, Crammond T. Single dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. Clin Pharmacol Ther 1992;52:487-495.
5. 5. Kalso E, Poyhia R, Onnela P, Linko K, Tigerstedt I, Tammisto T. Intravenous morphine and oxycodone for pain after abdominal surgery. Acta Anaesthesiol Scand 1991;35:642-646.
6. 6. Smith MJ, Breitbert WS, Platt MM. A critique of instruments and methods to detect, diagnose and rate delirium. J Pain Symptom Manage 1995;10:35-77.
7. 7. Breitbert W, Bruera E, Chochinov H, Lynch M. Neuropsychiatric syndromes and psychological symptoms in patients with advanced cancer. J Pain Symptom Manage 1995;10:131-141.
8. 8. Beaver W, Wallenstein S, Rogers A, Houde R. Analgesic studies of codeine and oxycodone in patients with cancer. 2. Comparisons of intramuscular oxycodone with intramuscular morphine and codeine. J Pharmacol Exp Ther 1978;207:101-108.
9. 9. Australian code of GMP for therapeutic goods: guidelines on tests for sterility. August 1990, Canberra, Australia, Australian Government Publications.
10. 10. Beaver WT, Wallenstein SL, Howde RW, Rogers A. Comparisons of the analgesic effect of oral and intramuscular oxymorphone and of intramuscular oxymorphone and morphine in patients with cancer. J Clin Pharmacol 1977;17:186-198.
11. 11. Cleary J, Kerry N, Mikus G, Somogyi A, Boxhner F. Enzyme kinetics of oxymorphone (OM) formation from oxycodone (OC) in rat and human liver microsomes (abstract). Clin Exp Pharmacol Physiol 1992;(suppl)21:15.
12. 12. Otton SV, Wu D, Joffe RT, Cheng SW, Sellers EM. Inhibition by fluoxetine of cytochrome P4502D6 activity. Clin Pharmacol Ther 1993;53: 401-409.
13. 13. Chen ZR, Somogyi AA, Reynolds G, Bochner F. Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. Br J Clin Pharmacol 1991;31:381-390.
14. 14. Eichelbaum M, Gross AS. The genetic polymorphism of debrisoquine/sparteine metabolism: clinical aspects. Pharmacol Ther 1990;46:377-394.
15. 15. Chen Z, Somogyi A, Bochner F. Simultaneous determination of dextromethorphan and three metabolites in plasma and urine using high performance liquid chromatography with application to their disposition in man. Ther Drug Monit 1990;12: 97-104.
16. 16. Kalso E, Vainio A. Hallucinations during morphine but not during oxycodone treatment (letter). Lancet 1988;56:912.
17. 17. Stiefel F, Fainsinger R, Bruera E. Acute confusional states in patients with advanced cancer. J Pain Symptom Manage 1992;7:94-98.
18. 18. Caraceni A, Martini C, De Conno F, Ventafridda V. Organic brain syndromes and opioid analgesia for cancer pain. J Pain Symptom Manage 1994;9:527-533.
19. 19. Ellison NM. Opioid analgesics for cancer pain: toxicities and their treatment In: Patt R, ed. Cancer Pain. Philadelphia: JB Lippincott, 1993, pp. 185-194.
20. 20. Bruera E, MacMillan K, Hansen J. The cognitive effect of the administration of narcotic analgesics in patients with cancer pain. Pain 1989;39:13-16.
21. 21. Fainsinger R, Bruera E. Treatment of delirium in a terminally ill patient. J Pain Symptom Manage 1992;7:54-56.
22. 22. McDonald N, Der L, Allen S, Champion F. Opioid hyperexcitability: the application of an alternate opioid therapy. Pain 1993;53:353-355.
23. 23. De Stoutz, Bruera E, Suarez-Almazor M. Opiate rotation (OR) for toxicity reduction in terminal cancer patients [abst]. In: Abstracts of the Seventh World Congress on Pain. Paris: IASP, 1993:331.
24. 24. Maddocks I, Parker D. Narcotic audit in 100 consecutive admissions to Daw House Hospice. Unpublished paper. July 1993.
25. 25. Rogers AG. The underutilization of oxycodone. J Pain Symptom Manage 1991;7:452.
26. 26. Poyhia R, Vainio A, Kalso E. A review of oxycodone's clinical pharmacokinetics and pharmacodynamics. J Pain Symptom Manage 1993;8:63-67.